{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:10Z","timestamp":1777934590373,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>First-line chemotherapy for advanced biliary tract cancers has been established as gemcitabine and cisplatin; however, there is currently no recognized standard second-line chemotherapy. The purpose of this study is to review and evaluate the outcomes of second-line chemotherapy for advanced biliary tract cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who received chemotherapy for unresectable or metastatic biliary tract cancers at BC Cancer between August 2009 and December 2015 were retrospectively studied to identify second-line chemotherapy treatments used and to determine overall survival, time-to-treatment discontinuation and characteristics predicting for improved overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 325 patients who received first-line chemotherapy for advanced biliary tract cancer, 90 (30%) received second-line chemotherapy. Median overall survival for patients who received only first-line chemotherapy was 9.5 months versus 17.3 months for patients who received second-line chemotherapy. Median time-to-treatment discontinuation for second-line chemotherapy was 2.0 months. Common drugs used in second-line chemotherapy treatments included capecitabine (30%), 5-fluorouracil and irinotecan (17%) and 5-fluorouracil monotherapy (15%). There was no difference in overall survival for patients who received single-agent second-line chemotherapy compared to doublet second-line chemotherapy<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients who are fit enough to receive second-line chemotherapy may benefit in terms of overall survival and should be offered treatment with single-agent therapy. Capecitabine was the most common second-line chemotherapy treatment. The improved median overall survival for patients who received second-line chemotherapy may be impacted by independent patient-specific factors which are unknown at this time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221122058","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T01:51:42Z","timestamp":1667353902000},"page":"1381-1386","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4194-2726","authenticated-orcid":false,"given":"Brittney","family":"Mathers","sequence":"first","affiliation":[{"name":"Department of Pharmacy, BC Cancer, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9289-7238","authenticated-orcid":false,"given":"Shirin","family":"Abadi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, BC Cancer, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine M","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, BC Cancer, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connor","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, BC Cancer, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, BC Cancer, Vancouver, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"bibr1-10781552221122058","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910283411807"},{"key":"bibr2-10781552221122058","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.01.001"},{"key":"bibr3-10781552221122058","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"bibr4-10781552221122058","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29471"},{"key":"bibr5-10781552221122058","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.003"},{"key":"bibr6-10781552221122058","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.446"},{"key":"bibr7-10781552221122058","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-016-9828-2"},{"key":"bibr8-10781552221122058","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.190"},{"key":"bibr9-10781552221122058","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"bibr10-10781552221122058","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.01.019"},{"key":"bibr11-10781552221122058","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.018"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221122058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221122058","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221122058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:30Z","timestamp":1777688850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221122058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1177\/10781552221122058"],"URL":"https:\/\/doi.org\/10.1177\/10781552221122058","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}